<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05093621</url>
  </required_header>
  <id_info>
    <org_study_id>2000029589</org_study_id>
    <nct_id>NCT05093621</nct_id>
  </id_info>
  <brief_title>Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure</brief_title>
  <acronym>TFO</acronym>
  <official_title>Torsemide Comparison With Furosemide for Management of Patients With Stable Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to be a prospective, randomized study is to compare the effectiveness&#xD;
      of two standard of care loop diuretics (furosemide versus torsemide) on clinical outcomes&#xD;
      among patients currently on a stable dose of loop diuretics.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized, unblinded, two-arm, multi-center clinical trial of patients&#xD;
      receiving loop diuretics for treatment of heart failure in an outpatient clinic. This study&#xD;
      will serve as additional enrollment for Cardio-Renal Effects of Torsemide vs. Furosemide: A&#xD;
      TRANSFORMHF Mechanistic Sub-Study (HIC 2000025867) which is currently only enrolling patients&#xD;
      admitted to the hospital for worsening heart failure. Thus allowing for expanded enrollment&#xD;
      into HIC 2000025867 with a more diverse group of heart failure patients. Participants will be&#xD;
      co-enrolled into this study and HIC 2000025867.&#xD;
&#xD;
      Patients will be randomized 1:1 to either oral torsemide OR oral furosemide (dosing at&#xD;
      discretion of local provider with dose equivalency guidance provided). This study will&#xD;
      include stable subjects seen at the outpatient setting. The initial and follow-up dosing of&#xD;
      torsemide and furosemide will be at healthcare provider discretion, with the following&#xD;
      conversion provided as a guide: 1 mg torsemide to 2-4 mg oral furosemide. For instance, a&#xD;
      patient would receive torsemide 20mg or furosemide 40-80 mg. Providers will be asked to&#xD;
      document their planned initial dose and dosing frequency of torsemide and furosemide&#xD;
      Randomization will occur within thirty days after the consent process and at the discretion&#xD;
      of the healthcare provider and research team. Following randomization, the study medication&#xD;
      is expected to constitute the oral diuretic therapy for one year. Patients will be prescribed&#xD;
      the randomized study medication on the day of randomization.&#xD;
&#xD;
      Dose adjustments will be at the discretion of the treating healthcare provider(s) with&#xD;
      strategies in place to maintain prescription of and adherence to the randomized medication.&#xD;
      All patients will have 30-day, and 12-month post-randomization phone contacts for assessment&#xD;
      of vital status, interval hospitalizations, concomitant HF medications, adherence, and&#xD;
      weight.&#xD;
&#xD;
      To achieve these goals, the investigators propose a multi-center 125-patient study that will&#xD;
      also co-enroll into Transform Ancillary (HIC 2000025867) a mechanistic sub-study of this&#xD;
      study and TRANSFORMHF.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 8, 2021</start_date>
  <completion_date type="Anticipated">August 14, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 14, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality, measured at 1 year.</measure>
    <time_frame>One year</time_frame>
    <description>All-cause mortality as measured by phone calls at 30 days and 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause hospitalization</measure>
    <time_frame>One year</time_frame>
    <description>All-cause hospitalization over one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospitalizations</measure>
    <time_frame>One year</time_frame>
    <description>• Total hospitalizations over one year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in weight</measure>
    <time_frame>One year</time_frame>
    <description>Change in weight over one year</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Furosemide, oral, dosage and frequency determined by treating physician or provider.&#xD;
1 mg torsemide to 2-4 mg oral furosemide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Torsemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Torsemide, oral, dosage and frequency determined by treating physician or provider.&#xD;
1 mg torsemide to 2-4 mg oral furosemide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>Standard of care diuretic</description>
    <arm_group_label>Furosemide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Torsemide</intervention_name>
    <description>Standard of care diuretic</description>
    <arm_group_label>Torsemide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a diagnosis of heart failure and who have been on a stable dose of a&#xD;
             diuretic for at least 30 days.&#xD;
&#xD;
          2. Plan for a daily outpatient oral loop diuretic regimen with anticipated need for long&#xD;
             term loop diuretic use&#xD;
&#xD;
          3. ≥ 18 years of age&#xD;
&#xD;
          4. Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. End-stage renal disease requiring dialysis therapy&#xD;
&#xD;
          2. Inability or unwillingness to comply with the study requirements&#xD;
&#xD;
          3. History of heart transplant or actively listed for heart transplant&#xD;
&#xD;
          4. Implanted left ventricular assist device or implant anticipated &lt;3 months&#xD;
&#xD;
          5. Pregnant or nursing women or women who are trying to conceive&#xD;
&#xD;
          6. Malignancy or other non-cardiac condition limiting life expectancy to &lt;12 months&#xD;
&#xD;
          7. Known hypersensitivity to furosemide, torsemide, or related agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Katherine Keith, RN</last_name>
    <phone>860-227-3925</phone>
    <email>katherine.keith@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Veena Rao, PHD</last_name>
    <phone>203-400-8101</phone>
    <email>veena.s.rao@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katherine Keith</last_name>
      <phone>203-737-3571</phone>
      <email>katherine.keith@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Veena Rao</last_name>
      <email>veena.s.rao@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Testani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 13, 2021</study_first_submitted>
  <study_first_submitted_qc>October 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Torsemide</mesh_term>
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

